Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by Bristol-Myers Squibb
Sponsor:
Collaborator:
AbbVie
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT01335399
First received: April 13, 2011
Last updated: July 23, 2014
Last verified: January 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2020
  Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)